Valuation: Galapagos NV

Market Cap 1.74B 1.98B 1.98B 1.61B 1.48B 2.8B 189B 2.85B 19.16B 7.51B 93.01B 7.43B 7.27B 321B P/E 2026 *
-9.06x
P/E 2027 * -10.4x
Enterprise Value -744M -848M -848M -689M -634M -1.2B -81.13B -1.22B -8.21B -3.22B -39.84B -3.18B -3.11B -138B EV / Sales 2026 *
-6.34x
EV / Sales 2027 * -5.53x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-12
Director of Finance/CFO 43 2025-07-06
Chief Tech/Sci/R&D Officer 61 2026-06-07
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-12
Change 5-day change 1-year change 3-year change Capi.($)
+0.44%+1.41%+4.36%+10.81% 50.73B
-1.57%-3.18%+383.82%+593.37% 39.73B
-0.14%+0.77%+27.49%-5.50% 34.69B
+1.76%-1.78%+21.44%+53.38% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.93%-1.01% - - 16.8B
-1.49%-6.18%+63.89%+120.53% 15.37B
+0.78%+1.16%+14.69%+17.32% 13.78B
-0.97%-2.83%+10.35%-33.29% 12.85B
Average -0.35%-0.96%+66.12%+98.53% 27.1B
Weighted average by Cap. -0.18%-0.35%+81.60%+124.23%

Financials

2026 *2027 *
Net sales 117M 134M 134M 109M 100M 189M 12.81B 193M 1.3B 508M 6.29B 502M 491M 21.72B 109M 125M 125M 101M 93.29M 176M 11.95B 180M 1.21B 474M 5.87B 469M 458M 20.26B
Net income -261M -297M -297M -241M -222M -420M -28.45B -428M -2.88B -1.13B -13.97B -1.12B -1.09B -48.25B -145M -166M -166M -134M -124M -234M -15.84B -239M -1.6B -629M -7.78B -622M -608M -26.87B
Net Debt -2.48B -2.83B -2.83B -2.3B -2.11B -4B -271B -4.07B -27.37B -10.73B -133B -10.61B -10.38B -459B -2.34B -2.67B -2.67B -2.17B -2B -3.77B -256B -3.85B -25.85B -10.14B -125B -10.02B -9.81B -433B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B